Comprehensive pharmaceuticals benefit assessment

On behalf of Bristol Myers Squibb, Polynomics has developed an instrument for the standardised benefit assessment of oncology drugs and proven its practicability for Switzerland in a cancer drug. The model based on the MCDA (Multi-Criteria Decision Analysis) method accounts for both patients’ and society’s use of pharmaceuticals. Experts from the various groups of players in the healthcare sector were involved in the tool’s development and validation. The proposed model can be used anywhere where pharmaceuticals benefit assessments are required in a regulatory context.